A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia
Study sponsor: AEON Biopharma, Inc. · AEON
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-07-11Actual
Enrollment · participants61Actual
Source updated2024-02-14Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.